Surrozen, Inc./DE Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Surrozen, Inc./DE (SRZN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 42.00 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-06
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 41.96K shares, a 424.46% increase year-over-year.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 43.00 shares, a 95.70% decline year-over-year.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 0.00 shares.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 12.00K shares.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 21.00K shares, a 110426.32% increase from fiscal 2024.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 19.00 shares, a 56.82% decline from fiscal 2023.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 44.00 shares, a 44.30% decline from fiscal 2022.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 79.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 41.96K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 42.00K shares 10-Q · filed 2026-08-06 | 42.00K shares derived: sum of 3 quarters · filed 2026-08-06 | 54.00K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 43.00 shares 10-Q · filed 2026-05-06 | 43.00 shares derived: sum of 2 quarters · filed 2026-05-06 | 12.04K shares derived: sum of 3 quarters · filed 2026-05-06 | 20.04K shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | 12.00K shares derived: sum of 2 quarters · filed 2026-03-23 | 20.00K shares derived: sum of 3 quarters · filed 2026-03-23 | 21.00K shares 10-K · filed 2026-03-23 |
| 2025-09-30 | 12.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | 20.00K shares derived: sum of 2 quarters · filed 2025-11-07 | 21.00K shares 10-Q · filed 2025-11-07 | 12.02K shares derived: sum of 4 quarters · filed 2025-11-07 |
| 2025-06-30 | 8.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | 9.00K shares 10-Q · filed 2025-08-08 | 19.00 shares derived: sum of 3 quarters · filed 2025-08-08 | 19.00 shares derived: sum of 4 quarters · filed 2025-08-08 |
| 2025-03-31 | 1.00K shares 10-Q · filed 2025-05-09 | -7.98K shares derived: sum of 2 quarters · filed 2025-05-09 | -7.98K shares derived: sum of 3 quarters · filed 2025-05-09 | 1.02K shares derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-12-31 | -8.98K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -8.98K shares derived: sum of 2 quarters · filed 2025-03-31 | 19.00 shares derived: sum of 3 quarters · filed 2025-03-31 | 19.00 shares 10-K · filed 2025-03-31 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 9.00K shares derived: sum of 2 quarters · filed 2024-11-06 | 9.00K shares 10-Q · filed 2024-11-06 | -636.96K shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 9.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 9.00K shares 10-Q · filed 2024-08-12 | -636.96K shares derived: sum of 3 quarters · filed 2024-08-12 | -445.96K shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-08 | -645.96K shares derived: sum of 2 quarters · filed 2024-05-08 | -454.96K shares derived: sum of 3 quarters · filed 2024-05-08 | -322.00 shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | -645.96K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-10 | -454.96K shares derived: sum of 2 quarters · filed 2024-04-10 | -322.00 shares derived: sum of 3 quarters · filed 2024-04-10 | 44.00 shares 10-K · filed 2024-04-10 |
| 2023-09-30 | 191.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 645.63K shares derived: sum of 2 quarters · filed 2023-11-08 | 646.00K shares 10-Q · filed 2023-11-08 | 646.00K shares derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-06-30 | 454.63K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 455.00K shares 10-Q · filed 2023-08-09 | 455.00K shares derived: sum of 3 quarters · filed 2023-08-09 | 455.04K shares derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | 366.00 shares 10-Q · filed 2023-05-10 | 368.00 shares derived: sum of 2 quarters · filed 2023-05-10 | 402.00 shares derived: sum of 3 quarters · filed 2023-05-10 | |
| 2022-12-31 | 2.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | 36.00 shares derived: sum of 2 quarters · filed 2023-03-31 | 79.00 shares 10-K · filed 2023-03-31 | |
| 2022-09-30 | 34.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 77.00 shares 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | 43.00 shares 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |